| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
IC50: 10 nM (SMOX), 790 nM (PAO), ＞60 μM (LSD1)[1]
JNJ-9350 targets spermine oxidase (SMOX), an enzyme that catalyzes the oxidation of spermine to spermidine, producing reactive oxygen species (ROS) as a byproduct. It is a potent and selective inhibitor of human SMOX with an IC50 of 8-10 nM. It shows remarkable selectivity over polyamine oxidase (PAOX) with an IC50 of 0.79 μM (>89-fold selectivity). |
|---|---|
| ln Vitro |
SMOX, PAO, and LSD1 have inhibitory effects when exposed to JNJ-9350 (0-100 μM), with IC50 values of 10 nM, 790 nM, and >60 μM, respectively[1]. The binding between SMOX and JNJ-9350 (1.1-70 μM) has a Ki value of 9.9 nM [1].
In vitro, JNJ-9350 potently inhibits human SMOX with an IC50 of 8-10 nM. It shows remarkable selectivity over PAOX (IC50 = 0.79 μM). In cellular assays, JNJ-9350 shows 91-108% recovery of SMOX in a cellular thermal shift assay (CETSA) with an IC50 of 1.2 μM. These in vitro activities support its use in studying polyamine metabolism and cancer biology. |
| ln Vivo |
1.19 JNJ-9350's Pharmacokinetic Properties in Mice [1]. Mice PO 10 milligrams per kilogram Total/Unbound Clearance (mL/min/kg): 73/5217 Distribution volume (L/kg) 1.7 Half-life in minutes 16 Mouse PPB 98.6% Oral F%: 34%
In vivo data for JNJ-9350 is not extensively reported in publicly available sources. As a potent and selective SMOX inhibitor, the compound has potential applications in animal models of cancer, where SMOX-derived ROS can promote tumor progression. By inhibiting SMOX, JNJ-9350 could reduce oxidative stress and tumor growth. However, specific published in vivo efficacy studies are not detailed in the current literature. JNJ-9350 is primarily used as a research tool for studying polyamine metabolism. |
| Enzyme Assay |
The in vitro SMOX inhibition assay for JNJ-9350 uses recombinant human SMOX enzyme and a substrate such as spermine. Enzyme activity is measured using a fluorometric or colorimetric assay that detects the production of hydrogen peroxide, and IC50 values are calculated from dose-response curves. Selectivity profiling against PAOX is performed using similar assay formats. Cellular target engagement is confirmed using CETSA.
|
| Cell Assay |
Cellular assays for JNJ-9350 are conducted in cancer cell lines where SMOX is expressed. Cells are treated with varying concentrations of JNJ-9350. SMOX activity is measured in cell lysates using activity assays. Cellular target engagement is assessed using CETSA, where the compound shows 91-108% recovery of SMOX with an IC50 of 1.2 μM. Cell viability and proliferation are measured using standard assays.
|
| Animal Protocol |
In vivo studies for JNJ-9350 would typically involve xenograft mouse models of cancer. The compound would be administered via oral or intraperitoneal routes at doses determined by pharmacokinetic studies. Efficacy would be assessed by measuring tumor growth inhibition, with pharmacodynamic markers such as polyamine levels and oxidative stress evaluated in tumor tissues. However, specific published in vivo protocols for JNJ-9350 are not available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for JNJ-9350 is not extensively reported in publicly available sources. The compound has a molecular weight of 422.48 g/mol and a molecular formula of C25H22N6O. It is soluble in DMSO. As a small molecule, it is expected to have moderate bioavailability. Detailed PK parameters such as half-life and bioavailability are not available in the current literature for this research compound.
|
| Toxicity/Toxicokinetics |
Toxicity data for JNJ-9350 is limited in publicly available sources. As with all research compounds, JNJ-9350 is intended for research use only and not for human therapeutic applications. Standard in vitro cytotoxicity assays and in vivo tolerability studies would be required for a complete toxicity assessment. The compound's selectivity for SMOX over PAOX suggests a favorable off-target profile.
|
| References | |
| Additional Infomation |
JNJ-9350 (CAS 326923-09-5) is a potent and selective inhibitor of spermine oxidase (SMOX) with an IC50 of 8-10 nM. It shows >89-fold selectivity over polyamine oxidase (PAOX). It has a molecular formula of C25H22N6O and a molecular weight of 422.48 g/mol. JNJ-9350 is a valuable research tool for studying polyamine metabolism, oxidative stress, and cancer biology.
|
| Molecular Formula |
C25H22N6O
|
|---|---|
| Molecular Weight |
422.482
|
| Exact Mass |
422.185
|
| CAS # |
326923-09-5
|
| PubChem CID |
3113005
|
| Appearance |
White to light brown solid powder
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
32
|
| Complexity |
605
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1N=CN(CCCNC(C2C=C3N(C(=CC(=N3)C3=CC=CC=C3)C3=CC=CC=C3)N=2)=O)C=1
|
| InChi Key |
RIGHCDSORZCRDE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H22N6O/c32-25(27-12-7-14-30-15-13-26-18-30)22-17-24-28-21(19-8-3-1-4-9-19)16-23(31(24)29-22)20-10-5-2-6-11-20/h1-6,8-11,13,15-18H,7,12,14H2,(H,27,32)
|
| Chemical Name |
N-(3-imidazol-1-ylpropyl)-5,7-diphenylpyrazolo[1,5-a]pyrimidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 5 mg/mL (11.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 0.5 mg/mL (1.18 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.5 mg/mL (1.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3670 mL | 11.8349 mL | 23.6698 mL | |
| 5 mM | 0.4734 mL | 2.3670 mL | 4.7340 mL | |
| 10 mM | 0.2367 mL | 1.1835 mL | 2.3670 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
